OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
New York, Feb. 22, 2016 -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, today announced that company CEO, Michael Nelson, will present at the New York Venture Capital Association 2016 Health & Bio Technology Summit on Tuesday, February 23rd at 4pm at the Microsoft Technology Center in New York, NY.
Intrommune’s lead product, INT-301, is being developed for the treatment of peanut allergies. Peanut allergy is a potentially deadly disease which affects 1.5 million children at an estimated cost of $6.25 billion per year to families in the United States. There is currently no treatment for this condition.
In addition to INT-301 for peanut allergy, Intrommune is also developing the OMIT platform to treat other common food allergies. The 8 most common allergies account for 90% of food allergies in the US. 15 million Americans, including 6 million children, have one or more food allergies.
About Oral Mucosal Immunotherapy
Food allergies affect an estimated 15 million Americans, including 6 million children, and over 220 million people worldwide. Allergen-specific immunotherapy is the only treatment modality that targets the root cause of the disease, consistently exposing the allergy sufferer’s immune system to small amounts of allergen proteins to desensitize them to the allergens over time. There is currently no commercially-available allergy immunotherapy product for food allergies. Oral mucosal immunotherapy (OMIT) uses a specially formulated toothpaste to stabilize and deliver allergenic extracts to the areas of the oral cavity with the greatest potential for allergy desensitization. OMIT promises advantages over existing approaches to allergy immunotherapy due to its targeted delivery, simplified administration, and ease of long-term patient adherence.
About Intrommune Therapeutics
Intrommune is developing the revolutionary oral mucosal immunotherapy (OMIT) treatment platform for food allergies. Intrommune’s lead product, INT-301, is expected to be a safe, effective and convenient therapy for patients who suffer from peanut allergy. OMIT is designed to deliver proteins, such as immunotherapeutic agents, to the immune system while the user brushes their teeth. OMIT is a long-term, patient-friendly, disease-modifying solution for the 220 million people, including 9 million adults and 6 million children in the U.S., who suffer from this life-altering condition.
Danya Glabau Director of Medical Affairs Intrommune Therapeutics [email protected]
